ArticleTranslational cancer research2025
A novel pyridazinone and thiophene compound IMB5043 activated apoptosis and autophagy in cisplatin-resistant non-small cell lung cancer cells.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is still one of the top three malignant tumors in the world at present and one of the cancers with the lowest survival rate. Cisplatin is one of the most commonly used chemotherapy drugs, but the development of drug resistance can lead to the death of patients who are ineffective to the treatment. IMB5043 is a pyridazinone and thiophene compound which is cytotoxic to cancer cells. This article aims to explore its effect on cisplatin-resistant lung cancer cells. Methods: Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay was used to detect the cyto-toxicity of different concentrations of cisplatin and IMB5043 on non-small cell lung cancer (NSCLC) H460 cells and its cisplatin-resistant cell (H460/DDP). The effect of IMB5043 on cell migration and invasion and its molecular mechanism were studied by scratch experiment, transwell experiment and Western blot. Hoechst 33342 staining, acridine orange/ethidium bromide (AO/EB) double fluorescence staining and Western blot were used to detect whether IMB5043 induced cell apoptosis and explore its molecular mechanism. Acridine orange (AO) staining and Western blotting were used to detect whether IMB5043 induced autophagy in cells. Results: IMB5043 induced the death of cisplatin-resistant NSCLC cells by activating apoptosis and autophagy, and inhibited the epithelial-mesenchymal transition (EMT) pathway to reduce cell migration and invasion. Conclusions: IMB5043 is an effective pyridazinone and thiophene derivatives with antitumor effects and may be suitable for cisplatin-based combination therapy in a subset of patients with cisplatin-resistant NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.